Plain-English translation of NCT06343090 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing two different treatment strategies for children and young adults with a type of blood cancer called B-cell acute lymphoblastic leukemia (B-ALL) that has either not responded to treatment or has returned after treatment. Both approaches use CAR T-cell therapy, which means doctors take your immune cells, train them in the lab to recognize and attack cancer cells, and then give them back to you. The trial compares giving two rounds of these trained cells in a row versus giving one round followed by a stem cell transplant.
When B-ALL comes back or doesn't respond to standard treatment, it becomes very difficult to treat and is life-threatening. This trial exists to find out which approach—using two different types of trained immune cells one after another, or using one type of trained immune cell followed by a stem cell transplant—works better for patients in this difficult situation.
You likely qualify if…
You likely don't qualify if…
If you join this trial, your doctor will assign you to one of two treatment groups based on what you and your medical team decide is best for your situation. In one group, you will receive two separate infusions of specially trained immune cells a few weeks apart. In the other group, you will receive one infusion of trained immune cells followed by a stem cell transplant. You will have regular visits to the hospital for monitoring, blood tests, and scans to check how well the treatment is working and to watch for any side effects. The trial will track how long you survive without the cancer getting worse and will continue to follow your health over time.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
China